How I treat ALK-positive non-small cell lung cancer

Since the discovery of anaplastic lymphocyte kinase (ALK) rearrangement in non-small cell lung cancer (NSCLC) and subsequent development of increasingly effective and central nervous system (CNS)-penetrant first-generation, second-generation and third-generation ALK tyrosine kinase inhibitors (TKIs)...

Descripción completa

Detalles Bibliográficos
Autores principales: McCusker, Michael G, Russo, Alessandro, Scilla, Katherine A, Mehra, Ranee, Rolfo, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677959/
https://www.ncbi.nlm.nih.gov/pubmed/31423342
http://dx.doi.org/10.1136/esmoopen-2019-000524

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6677959/
https://www.ncbi.nlm.nih.gov/pubmed/31423342
http://dx.doi.org/10.1136/esmoopen-2019-000524

Ejemplares similares